Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT010 versus PT003 and PT009 for COPD exacerbations over 52 weeks
2014-005671-92Phase 3Completed
- Sponsor
- Pearl Therapeutics
- Start
- Sep 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of budesonide, glycopyrronium, formoterol in chronic obstructive pulmonary disease (COPD), sponsored by Pearl Therapeutics. Started Sep 2015; status: completed.
02
Drugs
budesonideglycopyrroniumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2014-005671-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005671-92.